The replicability of oncolytic virus: defining conditions in tumor virotherapy.

The replicability of an oncolytic virus is measured by its burst size. The burst size is the number of new viruses coming out from a lysis of an infected tumor cell. Some clinical evidences show that the burst size of an oncolytic virus is a defining parameter for the success of virotherapy. This article analyzes a basic mathematical model that includes burst size for oncolytic virotherapy. The analysis of the model shows that there are two threshold values of the burst size: below the first threshold, the tumor always grows to its maximum (carrying capacity) size; while passing this threshold, there is a locally stable positive equilibrium solution appearing through transcritical bifurcation; while at or above the second threshold, there exits one or three families of periodic solutions arising from Hopf bifurcations. The study suggests that the tumor load can drop to a undetectable level either during the oscillation or when the burst size is large enough.

[1]  B. Hassard,et al.  Theory and applications of Hopf bifurcation , 1981 .

[2]  Dominik Wodarz,et al.  Towards Predictive Computational Models of Oncolytic Virus Therapy: Basis for Experimental Validation and Model Selection , 2009, PloS one.

[3]  D. Wodarz,et al.  Viruses as antitumor weapons: defining conditions for tumor remission. , 2001, Cancer research.

[4]  Dominik Wodarz,et al.  Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. , 2003, Human gene therapy.

[5]  Y. Tao,et al.  The competitive dynamics between tumor cells, a replication-competent virus and an immune response , 2005, Journal of mathematical biology.

[6]  Walter K. Hayman,et al.  Functions of a Complex Variable , 1969 .

[7]  R. Martuza,et al.  Oncolytic viral therapies – the clinical experience , 2005, Oncogene.

[8]  Lawrence M Wein,et al.  Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.

[9]  Eugene V Koonin,et al.  Mathematical modeling of tumor therapy with oncolytic viruses: Regimes with complete tumor elimination within the framework of deterministic models , 2006, Biology Direct.

[10]  Zeljko Bajzer,et al.  Mathematical modeling of cancer radiovirotherapy. , 2006, Mathematical biosciences.

[11]  H. Okano,et al.  An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor. , 2005, Cancer research.

[12]  J. Carr.  Applications of Centre Manifold Theory , 1981 .

[13]  Zeljko Bajzer,et al.  Modeling of cancer virotherapy with recombinant measles viruses. , 2008, Journal of theoretical biology.

[14]  L. Wein,et al.  Modeling and analysis of a virus that replicates selectively in tumor cells , 2001, Bulletin of mathematical biology.

[15]  E. Chiocca.  Oncolytic viruses , 2002, Nature Reviews Cancer.

[16]  Periodic solutions of a model for tumor virotherapy , 2010 .

[17]  J. Conway,et al.  Functions of a Complex Variable , 1964 .

[18]  M. Caligiuri,et al.  Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[19]  Eugene V Koonin,et al.  A community experiment with fully open and published peer review , 2006, Biology Direct.

[20]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[21]  Jianjun Paul Tian,et al.  Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. , 2006, Cancer research.